SaleMetabolic & GLP-1
Retatrutide
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD


Buy NA-Selank Canada | N-Acetyl Selank 10mg
Janoshik
Batch NSLK-CA-26G-10
Tuftsin-Analogue Anxiolytic Peptide
Also known as N-Acetyl Selank (Selank analogue)
N-Acetyl Selank is an N-acetylated form of Selank, a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, studied in research for anxiolytic and neuromodulatory signaling.
Mix & Match
1 vial — no vial discount yet.
Add 2 more vials for 5% off.
After that, 10% at 5 vials, 20% at 10 vials.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
N-Acetyl Selank is an N-acetylated form of Selank, a synthetic heptapeptide analogue of the immunomodulatory peptide tuftsin, studied in research for anxiolytic and neuromodulatory signaling.
Experimental models examine its peptidergic activity under controlled laboratory conditions.
Third-party tested for purity, ID, quantity.
Selank is a synthetic tuftsin analogue characterized in research for anxiolytic and neuromodulatory activity, including effects on GABAergic and monoaminergic signaling and on neurotrophic-factor expression. The N-acetylated form is studied for its peptide stability profile within the same research framework.
Studies span anxiolytic-model and neuroprotection research under structured conditions.
Selank was developed from research into stable analogues of the endogenous peptide tuftsin with neuromodulatory activity.
Research has characterized its anxiolytic and memory-related endpoints in model systems; the N-acetyl form shares this lineage.
Research into Selank-class peptides focuses on anxiolytic and neuromodulatory models. Frameworks evaluate peptidergic signaling, anxiolysis, and neurotrophic endpoints under controlled preclinical conditions.
3 of the 4 areas below are addressed directly by a paper cited on this page.
Addressed on this page by Kolik 2019, Konstantinopolsky 2022, Vyunova 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Vyunova 2018. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
Addressed on this page by Kolik 2019. Each is linked to its source record in the references below, so what was measured — and in what system — can be read rather than taken on trust.
No paper cited on this page reports on neuromodulation. This heading marks where NA-Selank is discussed in the category rather than a question the cited literature answers, and it is worth knowing which of these areas has work behind it and which does not.
The references section of this page cites 3 primary papers published between 2018 and 2022 — a thin record. Every citation is linked to its PubMed or DOI record so it can be read rather than taken on trust, and the summaries above describe what those papers report rather than what the compound is claimed to do.
Research compounds attract claims that outrun their evidence. Below are the ones most often encountered for NA-Selank, set against what the papers cited on this page actually report. Where the record is thin or contested, that is stated rather than smoothed over.
NA-Selank is also referred to as NA-selank, acetyl selank, and technically as N-Acetyl Selank (Selank analogue).
NA-Selank is commonly described online in connection with sharper focus, better memory and improved mood. In the research literature the same compound is filed under tuftsin-analogue peptide models, anxiolytic-signaling research and neurotrophic and memory studies.
The 3 papers cited on this page, published between 2018 and 2022 (2 in animal models) describe laboratory and animal work. None reports a controlled trial in humans. Findings in cell culture or in a rodent model describe what happened in that system; they do not establish that the same occurs in humans, and this compound is not approved for human use.
Nothing above is a statement of what this material does. It is a summary of what has been published and what has not. Eppix Labs supplies research materials only and provides no dosing, administration or protocol guidance.
Verification for NA-Selank is per lot, not per product. The current 10mg lot NSLK-CA-26G-10 returned 99.712% purity, 11.88 mg measured, 118.8% of the labelled 10 mg, assayed by Janoshik. Those figures are the laboratory's, published in full rather than reduced to a badge.
Purity is half the number. It states what fraction of the material in the vial is NA-Selank; it says nothing about how much material is in the vial, and a short-filled vial can return a purity result that is entirely accurate. The figure that answers the second question is measured mass against expected content — for NA-Selank, this lot measured 118.8% of its labelled 10 mg. Both numbers are published for every lot, whichever way they fall.
The lot code printed on the vial matches the code on the certificate for NA-Selank. Matching the two is what confirms the unit in hand came from the batch that was tested — a certificate not tied to a lot code proves nothing about any particular unit.
Researchers who buy NA-Selank in Canada through Eppix Labs receive the lot described by the certificate above: the code printed on the vial label is the code on the certificate, and both are searchable on the batch verification page.
NA-Selank is supplied as lyophilized powder. In the dry state the material is comparatively stable, which is why it ships at ambient temperature without a cold chain; once reconstituted it is a peptide in solution and the handling constraints tighten considerably. At 7 residues it is short enough to be produced by solid-phase synthesis, and the published sequence on this page is what an identity assay is checked against.
Repeated freeze-thaw cycling is the handling error most likely to degrade material of this class, because each cycle concentrates solutes at the ice boundary. Where a protocol calls for the same vial across multiple sessions, the published literature generally describes aliquoting after reconstitution rather than re-freezing the whole volume.
Vials may appear empty on arrival. Lyophilized material collects at the base of the vial and is often not visible until the vial is inspected under direct light.
Reconstitution materials are sourced separately. The reconstitution calculator on this site works out concentrations for a given volume, but it is an arithmetic tool for laboratory record-keeping and not a protocol.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of n acetyl selank. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity
PubMedSelank, a Peptide Analog of Tuftsin, Attenuates Aversive Signs of Morphine Withdrawal in Rats
PubMedSelank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus and Prefrontal Cortex in Rats
PubMedRelated
SaleMetabolic & GLP-1
Next-generation GLP receptor agonist studied for metabolic signaling and nutrient partitioning pathways
RETA-CA-26E-0199.637%
11.76 mg / 10 mg
$60.00$70.00CAD
SaleMetabolic & GLP-1
Dual incretin receptor agonist studied for glucose regulation, metabolic signaling, and weight pathway research
TIRZ-CA-26G-1099.634%
11.42 mg / 10 mg
$35.00$40.00CAD

Metabolic & GLP-1
Studied in metabolic research for its effects on glucose regulation, appetite signaling, and energy balance.
10 mgSEMA-CA-26F-1099.504%
11.27 mg / 10 mg
$70.00CAD

Metabolic & GLP-1
This product is supplied as eloralintide (LY3841136), a long-acting, selective amylin receptor agonist studied in research on metabolic and body-weight regulation.
10 mgELOR-CA-26G-1099.810%
12.42 mg / 10 mg
$150.00CAD